Capricor Therapeutics Faces Shareholder Lawsuit After FDA Trial Disclosures

The legal action, filed by Levi & Korsinsky, LLP, targets the period between December 17, 2025, and July 26, 2026. Investors allege that the company failed to disclose that its final statistical analysis plan for the HOPE-3 trial was never submitted to or agreed upon by the FDA. This discrepancy came to light through briefing documents released just before an advisory committee meeting, which ultimately resulted in a 9-3 vote against the efficacy of the company's treatment for Duchenne muscular dystrophy-associated cardiomyopathy.

Market reaction was swift and severe. CAPR shares, which reached a peak of $35.34 on April 21, 2026, plummeted to $4.19 by July 30. The decline occurred in two distinct stages: a 64% drop on July 27 following the release of the FDA documents, followed by an additional 36% loss as the advisory committee’s negative sentiment solidified. Shareholders who purchased stock during the class period and sustained losses have until September 28, 2026, to seek appointment as lead plaintiff in the case.